Clinical Trial Update: Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A in Patients With Fabry Disease [Phase 1]

View source ↗

Summary

This Phase 1 study reports pharmacokinetics, pharmacodynamics, and safety data for Moss-aGalactosidase A in patients with Fabry disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Moss-aGalactosidase A

Snippet

Sponsor: Greenovation Biotech GmbH | Conditions: Fabry Disease | Phase 1 | Status: COMPLETED